“Peptidyl Liposome for Trigger-Responsive Liposomal Delivery” by Associate Professor Hsien-Ming Lee, Institute of Chemistry, Academia Sinica. Time: 11:00 am Venue: B301 Department of Biochemistry Register
Author: Webmaster
Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation
Cholangiocarcinoma (CCA) is a difficult-to-treat cancer, with limited therapeutic options and surgery being the only curative treatment. Standard chemotherapy involves gemcitabine-based therapies combined with cisplatin,
Targeting MYC at the intersection between cancer metabolism and oncoimmunology
MYC activation is a known hallmark of cancer as it governs the gene targets involved in various facets of cancer progression. Of interest, MYC
In Silico and In Vitro Potential of FDA-Approved Drugs for Antimalarial Drug Repurposing against Plasmodium Serine Hydroxymethyltransferases
English Serine hydroxymethyltransferase (SHMT) is a key enzyme in deoxythymidylate synthesis pathway. It has been identified as a promising target for drug combating
Structure and biochemical characterization of an extradiol 3,4-dihydroxyphenylacetate 2,3-dioxygenase from Acinetobacter baumannii
English In this study, we report the structure and biochemical characterization of 3,4-Dihydroxyphenylacetate (DHPA) 2,3-dioxygenase (EC 1.13.11.15) from Acinetobacter baumannii (AbDHPAO), which is
A high catalytic efficiency and chemotolerant formate dehydrogenase from Bacillus simplex
English Formate dehydrogenase (FDH) catalyzes the reversible bioconversion of formate and NAD+ to produce carbon dioxide and NADH. FDH is biotechnologically important because it
BC Faculty Seminar: January 4, 2024
BC Faculty Seminar “The versatility of MarR domain in the regulation of phenolic compound utilization” by Assoc. Prof. Danaya Pakotiprapha Department of Biochemistry, Faculty of
Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma
Introduction: Bile duct cancer (cholangiocarcinoma, CCA) has a poor prognosis for patients, and despite recent advances in targeted therapies for other cancer types, it is still
BC Special Seminar: January 24, 2024
“Application of highly immunodeficient mice for cancer research and drug development” by Professor Seiji Okada, MD, PhD “Establishment and application of Patient-derived xenograft and cell
MicroRNA expression profiles associated with the metastatic ability of MDA‑MB‑231 breast cancer cells
Breast cancer is an important worldwide public health concern and its incidence increases every year. MicroRNAs (miRs/miRNAs) are small non-coding RNAs that control gene expression